Phase ii study of bendamustine in relapsed and refractory hodgkin lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Hodgkin Disease
  • Nitrogen Mustard Compounds

abstract

  • This study confirms the efficacy of bendamustine in heavily pretreated patients with HL. These results support current and future studies evaluating bendamustine combinations in relapsed and refractory HL.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3862960

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.45.3308

PubMed ID

  • 23248254

Additional Document Info

start page

  • 456

end page

  • 60

volume

  • 31

number

  • 4